RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS
Abstract
The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of somatostatin receptor (SSR) expression. These mechanisms can be exploited and this article discusses the important role of radionculide imaging and radionculide therapy in the management of NETs based on these mechanisms. This article reviews the current literature and discusses the role of radionuclide imaging in NETs both in terms of SSR imaging and neuroamine (metaiodobenzylguanidine [MIBG]) imaging. We discuss state-of- the-art 68Ga-radiopeptide imaging and indications for it use. We also discuss the role of 18F-FDG and other tracers in the management of NETs. The second half of the article focuses on radiotargeted treatment of NETs, discussing I-131 MIBG therapy and focussing on the emergence of peptide receptor radionuclide therapy. We discuss the clinical results, toxicities and patient selection for PRRT.
Key words: DOTA octreotide, DOTATATE, Ga-68, Lu-177, metaiodobenzylguanidine, neuroendocrine tumours, peptide receptor radionuclide therapy, Y-90
References
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
Modlin IM, Moss SF, Oberg K, et al. Gastrointestinal neuroendocrine (carcinoid) tumours: Current diagnosis and management. Med J Aust 2010;193:46-52.
Wieland DM, Brown LE, Tobes MC, et al. Imaging the primate adrenal medulla with [123I] and [131I] meta- iodobenzylguanidine: Concise communication. J Nucl Med 1981;22:358-64.
Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
van der Harst E, de Herder WW, Bruining HA, et al.[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.
Ru ni V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
Ramage JK, Williams R, Buxton-Thomas M. Imaging secondary neuroendocrine tumours of the liver: Comparison of I123 metaiodobenzylguanidine (MIBG) and in111- labelled octreotide (Octreoscan). QJM 1996;89:539-42.
Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.
Nocaudie-Calzada M, Huglo D, Carnaille B, et al. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med 1996;23:1448-54.
Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997;41:63-70. 11. Decristoforo C, Melendez-Alafort L, Sosabowski JK, et al. 99mTc HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: Preclinical evaluation and comparison with 111In octreotide. J Nucl Med 2000;41:1114-9.
de Herder WW, Kwekkeboom DJ, Valkema R, et al. Neuroendocrine tumors and somatostatin: Imaging techniques. J Endocrinol Invest 2005;28:132-6.
KrauszY,KeidarZ,KoganI,etal.SPECT/CThybridimaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59:565-73.
Perri M, Erba P, Volterrani D, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008;52:323-33.
CastaldiP,Ru niV,TregliaG,etal.Impactof111In-DTPA- octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med 2008;113:1056-67.
Wong KK, Cahill JM, Frey KA, et al. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol 2010;17:291-7.
Hillel PG, van Beek EJ, Taylor C, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol 2006;61:579-87.
Pettinato C, Sarnelli A, Di Donna M, et al. 68Ga- DOTANOC: Biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-9.
Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93.
Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal ndings on 111In-DTPA- octreotide scintigraphy. J Nucl Med 2010;51:875-82.
Mackenzie IS, Gurnell M, Balan KK, et al. The use of 18- uoro- dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 2007;157:533-7.
Rufini V, Treglia G, Castaldi P, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 2011;32:575-82.
King KS, Chen CC, Alexopoulos DK, et al. Functional imaging of SDHx-related head and neck paragangliomas: Comparison of 18F fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2 deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab 2011;96:2779-85.
Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101:1987-93.
Nwosu AC, Jones L, Vora J, et al. Assessment of the ef cacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 2008;98:1053-8
Gedik GK, Hoefnagel CA, Bais E, et al. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725-33.
Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162-8.
Navalkissoor S, Alhashimi DM, Quigley AM, et al. Ef cacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:904-12.
Sywak MS, Pasieka JL, McEwan A, et al. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 2004;28:1157-62.
Teunissen JJ, Kwekkeboom DJ, de Jong M, et al. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005;19:595-616.
Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: The rotterdam experience. Semin Nucl Med 2002;32:110-22.
Buscombe JR, Caplin ME, Hilson AJ. Long-term ef cacy of high activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44:1-6.
Virgolini I, Britton K, Buscombe J, et al. In- and Y-DOTA- lanreotide: Results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55.
Paganelli G, Bodei L, Handkiewicz Junak D, et al. 90Y-DOTA-D phe1-try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393-8.
Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-23.
Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147-56.
Gabriel M, Andergassen U, Putzer D, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010;54:92-9.
Bushnell DL Jr., O’Dorisio TM, O’Dorisio MS, et al 90Y edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652-9.
Baum RP, Soldner J, Schmucking M, et al. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumours. Eur J Nucl Med 2004;31:S238.
Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): A phase II study. Ann Oncol 2010;21:787-94.
Toumpanakis C, Caplin ME. Personal Communication Royal Free Hospital.
Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 lu-DOTA 0,Tyr3]octreotate: Toxicity, ef cacy, and survival. J Clin Oncol 2008;26:2124-30.
Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011;38:2125-35.
Claringbold PG, Brayshaw PA, Price RA, et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;38:302-11.
Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu- DOTATATE: Which is a better therapy option? Eur J Nucl Med Mol Imaging 2011;38:1788-97.
Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90) Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177) Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30:1100-6.
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800-16.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
